IN8bio, Inc. (INAB)

0.8950 +0.0136 (+1.54%) 收市：04:00PM EDT

IN8bio, Inc.

350 5th Avenue
Suite 5330
New York, NY 10118
United States
646 600 6438
https://in8bio.com

版塊: Healthcare
行業: Biotechnology
全職員工: 34

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Tai-Wei Ho	Co-Founder, President, CEO & Director	870k	無	1977
Mr. Patrick McCall CPA	CFO & Secretary	591.27k	無	1984
Dr. Trishna Goswami M.D.	Chief Medical Officer	668.51k	無	1979
Dr. Lawrence S. Lamb Ph.D.	Executive VP, Co-Founder & Chief Scientific Officer	482.47k	無	1955
Dr. Kate Rochlin Ph.D.	Chief Operating Officer	565.4k	無	1982
Mr. Michael McNamara	Vice President of Accounting	無	無	無
Dr. Glenn Schulman M.P.H., Pharm. D., Pharm.D.	VP and Head of IR & Corporate Communications	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of solid and liquid tumors. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM and other cancers; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company develops INB-300 and INB-500 that are in preclinical phase for treatment of acute myeloid leukemia, and other solid and hematological tumor types. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is based in New York, New York.

公司管治

截至 無 止，IN8bio, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。